Meanwhile, the UK launch of Freestyle Libre 3 comes as rival real-time CGM player Dexcom received a European CE mark for its G7 device for people with diabetes aged two years and older.

Looking forward, DexCom's management has reiterated its fiscal year 2025 forecast, anticipating revenue growth of 14% with a ...

Dexcom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an ...

DexCom reported Q4 revenue of $1.11 billion, surpassing estimates. The company reaffirmed its 2025 outlook while analysts ...

Medical device maker Dexcom beat fourth-quarter sales estimates helped by resilient demand for its continuous glucose monitors (CGMs) used by patients with diabetes.

San Diego, California-based DexCom, Inc. (DXCM) is a medical device company that focuses on the design, development, and ...

DexCom, Inc. DXCM reported fourth-quarter 2024 adjusted earnings per share (EPS) of 45 cents, which missed the Zacks ...

These are the kinds of stocks long-term investors will often be interested in, since they must have excellent, resilient ...

Persuade people with Type 1 diabetes to learn about the Dexcom G6 Continuous Glucose Monitor – overcoming low category/brand awareness. If people with T1D could choose any superpower, they'd choose ...

The FDA has cleared Dexcom’s Stelo as the first continuous glucose monitoring (CGM) device that does not need a prescription, which can be used by diabetics on oral medications, as well as non ...